Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) traded down 2.2% on Friday . The company traded as low as $0.43 and last traded at $0.45. 4,428 shares traded hands during trading, a decline of 99% from the average session volume of 411,149 shares. The stock had previously closed at $0.46.
A number of equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $1.25 target price on shares of Diffusion Pharmaceuticals in a research note on Monday, August 20th. ValuEngine raised shares of Diffusion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd.
The company has a market cap of $27.31 million, a price-to-earnings ratio of -0.39 and a beta of -1.75.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its earnings results on Monday, August 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. analysts forecast that Diffusion Pharmaceuticals Inc will post -0.42 EPS for the current year.
A hedge fund recently raised its stake in Diffusion Pharmaceuticals stock. Swift Run Capital Management LLC increased its holdings in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) by 261.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,508,017 shares of the company’s stock after acquiring an additional 1,814,806 shares during the period. Diffusion Pharmaceuticals makes up 1.0% of Swift Run Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding. Swift Run Capital Management LLC owned about 4.96% of Diffusion Pharmaceuticals worth $1,369,000 as of its most recent SEC filing. 7.63% of the stock is owned by institutional investors and hedge funds.
About Diffusion Pharmaceuticals (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
See Also: Fundamental Analysis
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.